MARKET

ABEO

ABEO

Abeona Therapeut
NASDAQ
6.40
+0.02
+0.31%
After Hours: 6.65 +0.25 +3.91% 19:48 11/08 EST
OPEN
6.43
PREV CLOSE
6.38
HIGH
6.45
LOW
6.25
VOLUME
195.08K
TURNOVER
--
52 WEEK HIGH
9.01
52 WEEK LOW
3.050
MARKET CAP
277.21M
P/E (TTM)
-2.9985
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ABEO last week (1028-1101)?
Weekly Report · 6d ago
Abeona Therapeutics® Announces Participation in November Investor Conferences
Barchart · 6d ago
Abeona Therapeutics announces new employee inducement grants
TipRanks · 11/01 11:38
ABEONA THERAPEUTICS® ANNOUNCES NEW EMPLOYEE INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 11/01 11:30
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $15 Price Target
Benzinga · 10/31 11:59
Abeona Therapeutics’ Strategic Advances Bolster Buy Rating and $15 Price Target
TipRanks · 10/31 10:27
Abeona Therapeutics Price Target Maintained With a $18.00/Share by Cantor Fitzgerald
Dow Jones · 10/29 15:59
Cantor Fitzgerald Reiterates Overweight on Abeona Therapeutics, Maintains $18 Price Target
Benzinga · 10/29 15:49
More
About ABEO
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Company’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

Webull offers Abeona Therapeutics Inc stock information, including NASDAQ: ABEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABEO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABEO stock methods without spending real money on the virtual paper trading platform.